Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease

@inproceedings{Chase2016DonepezilPS,
  title={Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease},
  author={Thomas N. Chase and Martin R. Farlow and Kathleen Clarence-Smith},
  booktitle={Neurotherapeutics},
  year={2016}
}
Available cholinergic drugs for treating Alzheimer’s disease (AD) provide modest symptomatic benefit. We hypothesized that co-administration of a peripheral anticholinergic to reduce dose-limiting adverse effects (AEs) would enable the safe/tolerable use of higher cholinesterase inhibitor doses and thus improve their antidementia efficacy. A modified single-blind, ascending-dose, phase IIa study of donepezil plus solifenacin (CPC-201) lasting 26 weeks was conducted in 41 patients with probable… CONTINUE READING
2 Citations
43 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 43 references

High dose cholinesterase inhibitor treatment of Alzheimer’s disease

  • TN Chase, K. Clarence-Smith
  • AAIC Abstract #2729l,
  • 2015
3 Excerpts

Similar Papers

Loading similar papers…